CY1106285T1 - Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστου - Google Patents
Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστουInfo
- Publication number
- CY1106285T1 CY1106285T1 CY20061101772T CY061101772T CY1106285T1 CY 1106285 T1 CY1106285 T1 CY 1106285T1 CY 20061101772 T CY20061101772 T CY 20061101772T CY 061101772 T CY061101772 T CY 061101772T CY 1106285 T1 CY1106285 T1 CY 1106285T1
- Authority
- CY
- Cyprus
- Prior art keywords
- breast cancer
- tyrosine kinase
- invasive
- malignant
- epithelium
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 210000000981 epithelium Anatomy 0.000 abstract 5
- 230000003211 malignant effect Effects 0.000 abstract 4
- 210000002919 epithelial cell Anatomy 0.000 abstract 2
- 230000009466 transformation Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 208000030776 invasive breast carcinoma Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Χρησιμοποιείται ένας αναστολέας της τυροσίνης κινάσης του EGFR στη κατασκευή ενός φαρμάκου προς χρήση στη (α) μείωση της μεταμόρφωσης των επιθηλιακών κυττάρων από μία φυσιολογική σε μία κακοήθη κατάσταση σε ένα άνθρωπο χωρίς επεκτατικό (διηθητικό) καρκίνο του μαστού και (β) μείωση της μεταμόρφωσης των επιθηλιακών κυττάρων από μία ενδιάμεση κατάσταση, μεταξύ του φυσιολογικού επιθηλίου και του κακοήθους διηθητικού επιθηλίου, σε μία κακοήθη κατάσταση σε ένα άνθρωπο χωρίς διηθητικό καρκίνο του μαστού και (γ) πρόκληση ουσιαστικής αναστροφής του επιθηλιακού ιστού πίσω σε μία φυσιολογική κατάσταση από μία ενδιάμεση κατάσταση μεταξύ του φυσιολογικού επιθηλίου και του κακοήθους διηθητικού επιθηλίου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9925958.2A GB9925958D0 (en) | 1999-11-02 | 1999-11-02 | Therapeutic use |
PCT/GB2000/004190 WO2001032155A2 (en) | 1999-11-02 | 2000-11-01 | Use of egfr tyrosine kinase inhibitors for treating breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106285T1 true CY1106285T1 (el) | 2011-10-12 |
Family
ID=10863835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101772T CY1106285T1 (el) | 1999-11-02 | 2006-12-11 | Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστου |
Country Status (21)
Country | Link |
---|---|
US (1) | US7553815B1 (el) |
EP (1) | EP1272188B1 (el) |
JP (1) | JP2003513035A (el) |
KR (1) | KR100785359B1 (el) |
CN (1) | CN1197577C (el) |
AT (1) | ATE339957T1 (el) |
AU (1) | AU779190B2 (el) |
BR (1) | BR0015194A (el) |
CA (1) | CA2389411C (el) |
CY (1) | CY1106285T1 (el) |
DE (1) | DE60030889T2 (el) |
DK (1) | DK1272188T3 (el) |
ES (1) | ES2275556T3 (el) |
GB (1) | GB9925958D0 (el) |
IL (1) | IL149176A0 (el) |
MX (1) | MXPA02004272A (el) |
NO (1) | NO323206B1 (el) |
NZ (1) | NZ518696A (el) |
PT (1) | PT1272188E (el) |
WO (1) | WO2001032155A2 (el) |
ZA (1) | ZA200203431B (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030007640A (ko) | 2000-05-19 | 2003-01-23 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
US20050038048A1 (en) * | 2001-10-29 | 2005-02-17 | Ball Howard Ashley | Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases |
EP1769795B1 (en) * | 2001-12-03 | 2013-07-24 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
EP1803821B1 (en) * | 2002-06-05 | 2012-02-29 | Cedars-Sinai Medical Center | Methods for managing kinase inhibitor therapy |
WO2005017493A2 (en) * | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
MXPA06003113A (es) | 2003-09-19 | 2006-06-20 | Astrazeneca Ab | Derivados de quinazolina. |
WO2005039588A2 (en) * | 2003-10-22 | 2005-05-06 | Novartis Ag | Methods for determining the risk of developing liver and lung toxicity |
US7701341B2 (en) * | 2004-09-01 | 2010-04-20 | Microsoft Corporation | Device service provider interface |
US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
RU2404806C2 (ru) | 2005-02-23 | 2010-11-27 | Дженентек, Инк. | Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
CN101415422B (zh) | 2006-02-09 | 2012-11-07 | 第一三共株式会社 | 抗癌药用组合物 |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
CL2008000614A1 (es) | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her. |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
KR20110132371A (ko) * | 2009-03-11 | 2011-12-07 | 아디아 바이오사이언스즈 인크. | Rdea119/bay 869766을 포함하는 특정 암의 치료를 위한 제약 조합물 |
TW201544123A (zh) | 2009-03-20 | 2015-12-01 | Genentech Inc | 抗-her抗體 |
US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
JP2015500638A (ja) | 2011-11-30 | 2015-01-08 | ジェネンテック, インコーポレイテッド | 癌におけるerbb3変異 |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
EP2926142B2 (en) | 2012-11-30 | 2022-07-06 | F. Hoffmann-La Roche AG | Identification of patients in need of pd-l1 inhibitor cotherapy |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5795910A (en) * | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
MX9707453A (es) * | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
ES2203642T3 (es) * | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
ES2172670T3 (es) * | 1995-07-06 | 2002-10-01 | Novartis Ag | Pirrolpirimidinas y procedimientos para su preparacion. |
PL348634A1 (en) * | 1998-05-15 | 2002-06-03 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
DE602007005815D1 (de) | 2006-08-28 | 2010-05-20 | Koninkl Philips Electronics Nv | Verfahren und vorrichtung zur bilderweiterung |
-
1999
- 1999-11-02 GB GBGB9925958.2A patent/GB9925958D0/en not_active Ceased
-
2000
- 2000-11-01 JP JP2001534360A patent/JP2003513035A/ja active Pending
- 2000-11-01 KR KR1020027005551A patent/KR100785359B1/ko not_active IP Right Cessation
- 2000-11-01 AT AT00973002T patent/ATE339957T1/de not_active IP Right Cessation
- 2000-11-01 MX MXPA02004272A patent/MXPA02004272A/es active IP Right Grant
- 2000-11-01 CA CA002389411A patent/CA2389411C/en not_active Expired - Fee Related
- 2000-11-01 AU AU11559/01A patent/AU779190B2/en not_active Ceased
- 2000-11-01 EP EP00973002A patent/EP1272188B1/en not_active Expired - Lifetime
- 2000-11-01 IL IL14917600A patent/IL149176A0/xx not_active IP Right Cessation
- 2000-11-01 ES ES00973002T patent/ES2275556T3/es not_active Expired - Lifetime
- 2000-11-01 PT PT00973002T patent/PT1272188E/pt unknown
- 2000-11-01 WO PCT/GB2000/004190 patent/WO2001032155A2/en active IP Right Grant
- 2000-11-01 NZ NZ518696A patent/NZ518696A/xx not_active IP Right Cessation
- 2000-11-01 DE DE60030889T patent/DE60030889T2/de not_active Expired - Lifetime
- 2000-11-01 US US10/111,390 patent/US7553815B1/en not_active Expired - Fee Related
- 2000-11-01 BR BR0015194-7A patent/BR0015194A/pt not_active Application Discontinuation
- 2000-11-01 DK DK00973002T patent/DK1272188T3/da active
- 2000-11-01 CN CNB00815290XA patent/CN1197577C/zh not_active Expired - Fee Related
-
2002
- 2002-04-30 ZA ZA200203431A patent/ZA200203431B/xx unknown
- 2002-04-30 NO NO20022065A patent/NO323206B1/no not_active IP Right Cessation
-
2006
- 2006-12-11 CY CY20061101772T patent/CY1106285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001032155A3 (en) | 2002-05-10 |
DE60030889D1 (de) | 2006-11-02 |
DE60030889T2 (de) | 2007-04-05 |
ES2275556T3 (es) | 2007-06-16 |
WO2001032155A2 (en) | 2001-05-10 |
US7553815B1 (en) | 2009-06-30 |
NO20022065L (no) | 2002-06-24 |
KR20020064306A (ko) | 2002-08-07 |
NZ518696A (en) | 2004-12-24 |
MXPA02004272A (es) | 2003-08-20 |
CA2389411C (en) | 2009-09-01 |
AU779190B2 (en) | 2005-01-13 |
BR0015194A (pt) | 2002-06-18 |
EP1272188B1 (en) | 2006-09-20 |
PT1272188E (pt) | 2007-01-31 |
DK1272188T3 (da) | 2007-01-29 |
ZA200203431B (en) | 2003-02-26 |
NO20022065D0 (no) | 2002-04-30 |
KR100785359B1 (ko) | 2007-12-18 |
IL149176A0 (en) | 2002-11-10 |
GB9925958D0 (en) | 1999-12-29 |
NO323206B1 (no) | 2007-01-22 |
AU1155901A (en) | 2001-05-14 |
ATE339957T1 (de) | 2006-10-15 |
CN1387437A (zh) | 2002-12-25 |
JP2003513035A (ja) | 2003-04-08 |
EP1272188A2 (en) | 2003-01-08 |
CN1197577C (zh) | 2005-04-20 |
CA2389411A1 (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106285T1 (el) | Χρηση αναστολεων της τυροσινης κινασης του egfr για τη θepαπεια του καρκινου του μαστου | |
CY1122817T1 (el) | Νεα αντι-il 13 αντισωματα και χρησεις αυτων | |
CY1110256T1 (el) | Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου | |
HK1068261A1 (en) | Combinations comprisinga selective cyclooxygenase-2 inhibitor | |
DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
CY1105634T1 (el) | Η χρηση του ραδιου -223 για τη στοχευση ασβεστωμενων ιστων για την ανακουφιση πονου και τη θεραπεια οστικου καρκινου | |
BR9910511A (pt) | Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
CY1112753T1 (el) | Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743 | |
EA200200246A1 (ru) | Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки | |
CY1108462T1 (el) | Χρηση της αναστροζολης για τη θεραπευτικη αντιμετωπιση μετεμμηνοπαυσιακων γυναικων με καρκινο του μαστου σε πρωιμο σταδιο | |
PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
PT1255538E (pt) | Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros | |
CY1105269T1 (el) | Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης) | |
ATE373711T1 (de) | Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten | |
RS37804A (en) | Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy | |
NZ538926A (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
ITPD20020003A1 (it) | Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori. | |
CY1114343T1 (el) | Μεθοδος για τη θεραπεια του καρκινου του τραχηλου της μητρας | |
UA40393A (uk) | Спосіб лікування хронічного обструктивного бронхіту | |
UA32302A (uk) | Спосіб усунення післяопераційних деформацій м'яких тканин |